Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Smruthi Organics Ltd (SMRUTHIORG) is currently trading at 117.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Smruthi Organics Limited specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) focusing on anti-diabetic, anti-hypertension, and anti-infectives categories. They cater to a global clientele across Asia, Americas, and Africa. The company operates two manufacturing facilities in Solapur, India, and has progressively expanded its product offerings since its incorporation in 1989. In 2021-22, the Finished Dosage Formulations (FDF) division was fully operational, showcasing industrial advancement and scaling the company's capacity to deliver pharmaceutical products comprehensively. Smruthi Organics has expanded its brand portfolio with the launch of 'ENERLIN' and 'SOLSITA', highlighting their commitment to innovation and market diversification.
Over the past 52 weeks, Smruthi Organics Ltd has traded between a low of ₹103.00 and a high of ₹164.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Smruthi Organics Ltd has a market capitalization of approximately 135.01. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Smruthi Organics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.50 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 135.01 Cr, Smruthi Organics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Smruthi Organics Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Smruthi Organics Ltd is 29.50. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
4
Neutral
7
Bullish
3
Bearish
22
Neutral
7
Bullish
17
Bearish
18
Neutral
0
Bullish
14
Regulatory Approval
Smruthi Organics received a Certificate of Suitability (CEP) from EDQM for Amlodipine Besilate, enabling supply to EU and other CEP‑recognizing markets and strengthening its regulated‑market prospects.
Regulatory Approval
Company received a Certificate of Suitability (CEP) from EDQM for Amlodipine Besilate, enabling supply to European and other CEP-recognizing markets and strengthening its regulatory portfolio.
Smruthi Organics Limited specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) focusing on anti-diabetic, anti-hypertension, and anti-infectives categories. They cater to a global clientele across Asia, Americas, and Africa.
The company operates two manufacturing facilities in Solapur, India, and has progressively expanded its product offerings since its incorporation in 1989.
In 2021-22, the Finished Dosage Formulations (FDF) division was fully operational, showcasing industrial advancement and scaling the company's capacity to deliver pharmaceutical products comprehensively.
Smruthi Organics has expanded its brand portfolio with the launch of 'ENERLIN' and 'SOLSITA', highlighting their commitment to innovation and market diversification.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs
135 Cr
Low Risk
29.5
56.7
—
1.9
164.00
103.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
30.01 | 142 Cr | 15.71 | 12.26 | 0.00 | 70.62 | 33.57 | 8.92 | |
105.00 | 136 Cr | 11.24 | 0.99 | 0.77 | 8.89 | 11.28 | 7.21 | |
118.30 | 135 Cr | 29.50 | 1.91 | 1.27 | 6.60 | 10.56 | 4.61 | |
55.11 | 119 Cr | -5.20 | 0.00 | 0.00 | 14.21 | -14.91 | -13.78 | |
94.70 | 118 Cr | 25.32 | 1.90 | 0.00 | 7.24 | 10.49 | 3.50 | |
110.00 | 113 Cr | 16.57 | 0.80 | 2.72 | 6.85 | 9.26 | 4.35 | |
90.29 | 111 Cr | 7.99 | 1.04 | 0.00 | 9.10 | 12.39 | 10.91 |
